Abstract
Background
Nephrotic syndrome (NS) is characterized by water and sodium retention, which leads to edema. The non-osmotic stimulation of arginine vasopressin release from the pituitary gland has been implicated as one of the important factors in abnormal water retention in patients with NS.
Case-Diagnosis/Treatment
We present the initial description of a patient with massive edema caused by refractory nephrotic syndrome, which was effectively treated with tolvaptan, a selective oral vasopressin V2 receptor antagonist.
Conclusions
Tolvaptan is effective for the treatment of massive edema caused by NS. Larger studies are needed in the future to fully assess the value and safety of tolvaptan use for this condition.
This is a preview of subscription content, log in via an institution to check access.
References
Rascher W, Tulassay T (1987) Hormonal regulation of water metabolism in children with nephrotic syndrome. Kidney Int Suppl 21:S83–S89
Usberti M, Federico S, Meccariello S, Cianciaruso B, Balletta M, Pecoraro C, Sacca L, Ungaro B, Pisanti N, Andreucci VE (1984) Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome. Kidney Int 25:422–429
Pedersen EB, Danielsen H, Madsen M, Jensen T (1985) Defective renal water excretion in nephrotic syndrome: the relationship between renal water excretion and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. Eur J Clin Invest 15:24–29
Tulassay T, Rascher W, Lang RE, Seyberth HW, Schärer K (1987) Atrial natriuretic peptide and other vasoactive hormones in nephrotic syndrome. Kidney Int 31:1391–1395
Pyo HJ, Summer SN, Niederberger M, Kim JK, Schrier RW (1995) Arginine vasopressin gene expression in rats with puromycin-induced nephrotic syndrome. Am J Kidney Dis 25:58–62
Gassanov N, Semmo N, Semmo M, Nia AM, Fuhr U, Er F (2011) Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 67:333–346
Peri A (2013) Clinical review: the use of vaptans in clinical endocrinology. J Clin Endocrinol Metab 98:1321–1332
Apostol E, Ecelbarger CA, Terris J, Bradford AD, Andrews P, Knepper MA (1997) Reduced renal medullary water channel expression in puromycin aminonucleoside-induced nephrotic syndrome. J Am Soc Nephrol 8:15–24
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shimizu, M., Ishikawa, S., Yachi, Y. et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol 29, 915–917 (2014). https://doi.org/10.1007/s00467-013-2687-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-013-2687-1